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Objective
• To determine the prevalence and clinical correlates of the
G84E mutation in the homeobox transcription factor, or
HOXB13, gene using DNA samples from 9559 men with
prostate cancer undergoing radical prostatectomy.
Patients and Methods
• DNA samples from men treated with radical prostatectomy
at the University of Michigan and John Hopkins University
were genotyped for G84E and this was conﬁrmed by Sanger
sequencing.
• The frequency and distribution of this allele was determined
according to speciﬁc patient characteristics (family history,
age at diagnosis, pathological Gleason grade and stage).
Results
• Of 9559 patients, 128 (1.3%) were heterozygous carriers of
G84E.
• Patients who possessed the variant were more likely to have
a family history of prostate cancer than those who did not
(46.0 vs 35.4%; P = 0.006).
• G84E carriers were also more likely to be diagnosed at a
younger age than non-carriers (55.2 years vs 58.1 years;
P < 0.001).
• No diﬀerence in the proportion of patients diagnosed with
high grade or advanced stage tumours according to carrier
status was observed.
Conclusions
• In the present study, carriers of the rare G84E variant in
HOXB13 were both younger at the time of diagnosis and
more likely to have a family history of prostate cancer
compared with homozygotes for the wild-type allele.
• No signiﬁcant diﬀerences in allele frequency were detected
according to selected clinical characteristics of prostate
cancer.
• Further investigation is required to evaluate the role of
HOXB13 in prostate carcinogenesis.
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Introduction
The ﬁndings from epidemiological studies indicate that there
is a familial component to prostate cancer. Family history,
particularly among ﬁrst-degree relatives, is a strong risk factor
for prostate cancer with an ∼2- to 2.5-fold increase in risk
associated with a positive history of disease. Risk has been
shown to increase with the number of aﬀected relatives and is
inversely related to the age at diagnosis among those relatives
[1]; however, the speciﬁc genes that explain the observed
associations have largely eluded researchers for decades.
Recently, we discovered a rare, recurrent mutation in the
HOXB13 gene, G84E, which was associated with a signiﬁcant
increase (∼10- to 20-fold) in the risk of prostate cancer. The
frequency of the variant was 1.4% in all men with prostate
cancer in the study and increased to 3.1% among men
diagnosed with early-onset and familial prostate cancer [2].
The homeobox transcription factor gene HOXB13, located
on the long arm of chromosome 17 (17q21), belongs to a
superfamily of genes considered critical to animal embryonic
development and characterized by a highly conserved
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DNA-binding domain.HOXB13 is thought to play a role
in the development of the prostate gland; however, the
expression of its protein remains elevated into adulthood.
The mechanism whereby HOXB13 inﬂuences prostate
carcinogenesis is currently unknown, but it is certain to be an
area of intense investigation.
A number of studies have subsequently conﬁrmed the
presence of the G84E mutation and its association with
familial and hereditary prostate cancer [3–8]. In the present
investigation, we set out to determine the prevalence of G84E
in a large case series of men with prostate cancer undergoing
radical prostatectomy at one of two institutions, representing a
population of men with both sporadic and familial disease.
Because of the relative rarity of the mutation, this large sample
of patients enables us to examine clinical characteristics that
inﬂuence survival by carrier status, which may provide
valuable clues as to the function of the gene in prostate cancer.
Patients and Methods
Study Subjects
Eligible patients were diagnosed at any age with primary
prostate cancer, histologically conﬁrmed, and treated with
radical prostatectomy at either the University of Michigan
Medical Center (UM) (n = 1511) between 1999 and 2012 or
Johns Hopkins University Hospital (JHU) (n = 8048) between
1993 and 2012. Note that a proportion (39%) of these patients
was also included in our initial report describing the HOXB13
G84E mutation in men with prostate cancer [2]. Demographic
and clinical information collected on each patient included
date of and age at diagnosis (UM), date of and age at radical
prostatectomy (UM and JHU), race, family history of prostate
cancer, pathological Gleason grade, pathological (TNM) stage,
and surgical margin status. Patients were followed passively for
disease recurrence, additional treatment(s), and vital status
through 2012. The protocol and consent documents were
approved by the institutional review boards at each institution.
Genotyping Methods
DNA was extracted from whole blood using standard
methods. Samples were genotyped using the MassARRAY
system (Sequenom) or Taqman assay (rs138213197; Applied
Biosystems, Foster City, CA, USA). All G84E mutation carriers
who were identiﬁed on either platform and a randomly
selected subset of samples (∼10%) were subjected to duplicate
genotyping using Sanger sequencing in a blinded fashion, with
100% concordance among duplicate samples.
Statistical Analysis
All analyses were conducted using SAS software (SAS Inc.
v.9.2, Cary, NC, USA). The genotype frequencies for G84E
were tested for and consistent with Hardy–Weinberg
equilibrium (P > 0.05).We calculated the distribution of
categorical variables among all subjects and the median and
range for all continuously measured variables of interest. As
there were no homozygotes for the variant allele, the
frequency of carriers was determined among all subjects.
Simple chi-squared tests were used to compare the frequencies
for select characteristics between carriers and non-carriers of
G84E. Breslow–Day chi-squared tests were used to evaluate
the potential for eﬀect modiﬁcation by age at diagnosis on the
association between genotype and both family history and
Gleason sum. P values < 0.05 were considered to indicate
statistical signiﬁcance.
Results
Selected characteristics and the genotype frequencies for G84E
of the 9559 patients with prostate cancer included in our
investigation are shown in Table 1. Age at diagnosis was
available for 98% of UM patients; the median (range) age was
59 (38–77) years. For the remaining 2% of patients with
missing information, we used age at surgery to obtain an
approximate age at diagnosis as there was a mean diﬀerence of
just 4 months between age at diagnosis and age at surgery in
the UM series. Age of surgery was available for JHU patients;
the age distribution was similar to that of the UM series
(median [range] 58 [33–77] years). Approximately 85% of UM
patients and 88% of JHU patients were white, and ∼36% of
patients at each institution had a documented family history
of prostate cancer in a ﬁrst- or second-degree relative. A
greater proportion of UM patients had high (4 + 3 and higher)
Gleason grade tumours, and elevated pre-treatment PSA
(≥10 ng/mL) compared with JHU patients. Conversely, a
greater proportion of JHU patients were diagnosed with
non-organ-conﬁned disease (≥T3a) compared with UM
patients. The G84E carrier rate was 1.3% among all patients,
with no appreciable diﬀerence in the proportion of patients
possessing the risk allele between the JHU (1.4%) and the UM
group (1.1%). No homozygous carriers were detected. As
mutation carriers were almost exclusively white (two patients
of unknown race were carriers), the remaining analysis was
restricted to the 8341 white patients in the study.
Table 2 shows the associations between the G84E genotype
and selected clinical characteristics at the time of diagnosis.
G84E carriers in the present study were more likely to be
diagnosed at a younger age compared with non-carriers (55.2
vs 58.1 years; P < 0.001). Patients who possessed the variant
were also more likely to have a family history of prostate
cancer (46.0 vs 35.4%; P = 0.006). Regression model analysis of
the probability of being diagnosed with early-onset prostate
cancer (≤60 years), mutually adjusting for both G84E genotype
and family history, we observed a nearly twofold increase in
the odds of early-onset disease associated with the mutation
(odds ratio [OR] 1.90; 95% CI 1.23–2.94), which was slightly
higher than the OR detected for family history (OR 1.45; 95%
G84E mutation in the HOXB3 gene and prostate cancer
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CI 1.32–1.59). No diﬀerence was observed in the proportion of
patients with high grade tumours by carrier status (16.7% of
carriers vs 17.5% of non-carriers had tumours with Gleason
sum ≥ 4 + 3; P = 0.95). Likewise, there was no diﬀerence
in the proportion of patients diagnosed with advanced stage
(≥pT3a) tumours by carrier status (24.6 vs 27.5%; P = 0.52).
Finally, our analysis of the various relationships between
carrier status and clinical measures of interest did not provide
evidence for eﬀect modiﬁcation between G84E and family
history of disease on age at diagnosis, tumour stage or
Gleason sum.
Discussion
The results of the present study conﬁrm the presence of the
prostate cancer susceptibility allele HOXB13 G84E variant in a
subset of men with prostate cancer. The observed prevalence
of the risk allele (1.3%) among all patients was consistent with
previous estimates [4,6], including our own [2]. G84E carriers
were more likely to have been diagnosed at a younger age and
have a positive family history of prostate cancer compared
with non-carriers; however, we did not observe any diﬀerence
in the distribution of Gleason grade or tumour stage between
carriers and non-carriers of the G84E mutation.
Our research team was the ﬁrst to report the association
between HOXB13 and prostate cancer [2] with the initial
discovery of the G84E variant as a result of targeted
sequencing of 202 genes in a 15.5 Mb candidate region on
17q21–22. This region was identiﬁed in a linkage analysis of
pedigree data from 175 families with hereditary prostate
cancer participating in the University of Michigan Prostate
Cancer Genetics Project (PCGP) [9]. The probands (the
youngest case with DNA) from four families (three from
PCGP and one from JHU) with the strongest evidence for
linkage in this region were all observed to harbour a
substitution G→A in the second position of codon 84
resulting in the replacement of glycine by glutamic acid.
Subsequent genotyping of family members observed near
complete cosegregation of the mutation with disease among
aﬀected relatives with just one unaﬀected carrier of G84E.
Finally, an OR of 20.1 (P = 8.5 × 10−7), and a carrier frequency
of 1.4% among cases, was reported in a case–control study of
5011 cases and 1401 controls, also from the UM and JHU [2].
In our initial report examining clinical characteristics and
their relationship to G84E carrier status, we included all cases
available to us, including a large number of cases from the
hereditary prostate cancer studies at each of our institutions.
In the present report, we included men presenting for radical
prostatectomy, not speciﬁcally selected for early-onset and/or
family history of disease.
The International Consortium for Prostate Cancer Genetics
(ICPCG) conﬁrmed the presence of G84E in 112 (4.6%) of the
2443 families (all of European descent) participating in the
consortium. After exclusion of PCGP and JHU participants, an
OR for prostate cancer of 4.3 (95% CI 2.32, 7.96) was reported
among G84E carriers in the remaining ICPCG families [5].
Several studies have reported measures of association
of prostate cancer with G84E ranging from 3.3 to 8.8
[3,4,6–8,10,11] and, with one exception [4], stronger estimates
among men with early-onset, familial and hereditary prostate
cancer. Stott-Miller et al. [4], observed a fourfold increase in
Table 1 Demographic and tumour characteristics of the patients with
prostate cancer.
Characteristic UM, n (%) JHU, n (%)
Total cases 1511 8048
Age at diagnosis/surgery*
≤60 years 873 (57.8) 5119 (63.6)
>60 years 638 (42.2) 2929 (36.4)
Race
White 1289 (85.3) 7052 (87.6)
Black 98 (6.5) 622 (7.7)
Other/unknown 124 (8.2) 374 (4.6)
Family history
Yes 540 (35.7) 2862 (35.6)
No 893 (59.1) 4567 (56.7)
Unknown 78 (5.2) 619 (7.7)
Year of surgery
1990–1999 55 (3.6) 592 (7.4)
2000–2009 1135 (75.1) 6533 (81.2)
2010–2012 321 (21.2) 923 (11.5)
Preoperative PSA, ng/mL
<2.5 112 (7.4) 1568 (19.5)
2.5–4.0 181 (12.0) 1309 (16.3)
4.0–10.0 933 (61.7) 4463 (55.5)
≥10.0 247 (16.3) 686 (8.5)
Unknown 38 (2.5) 22 (0.3)
Pathological Gleason score
<7 378 (25.0) 4563 (56.7)
7 (3 + 4) 735 (48.6) 2107 (26.2)
7 (4 + 3) 260 (17.2) 810 (10.1)
>7 87 (5.8) 533 (6.6)
Unknown 51 (3.4) 35 (0.4)
Pathological T-stage
pT2 1260 (83.4) 5650 (70.2)
pT3a 186 (12.3) 1954 (24.1)
pT3b 48 (3.2) 402 (5.1)
pT3x 0 (0.0) 2 (0.0)
pT4 10 (0.7) 0 (0.0)
Unknown/pTx 7 (0.5) 40 (0.5)
Pathological N-stage
N1 14 (0.9) 164 (2.0)
N0/N2/Nx 1497 (99.1) 7884 (98.0)
PSA recurrence
Yes 101 (6.7) 655 (8.1)
No 1383 (91.5) 7230 (89.8)
Unknown 27 (1.8) 163 (2.0)
Surgical margins
Yes 217 (14.4) 1122 (13.9)
No 1269 (84.0) 6880 (85.5)
Unknown 25 (1.7) 46 (0.6)
Seminal vesicle invasion
Yes 53 (3.5) 365 (4.5)
No 1440 (95.3) 7681 (95.4)
Unknown 18 (1.2) 2 (0.0)
Genotype at rs138213197
GG 1494 (98.9) 7937 (98.6)
GA 17 (1.1) 111 (1.4)
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the likelihood of diagnosis associated with G84E among men
with no family history of prostate cancer, but only a 1.5-fold
increase among men with a positive family history in a
ﬁrst-degree relative. The same investigation suggested the risk
allele was also associated with higher grade and advanced
stage disease, a ﬁnding not replicated by others including the
present study [10,12]. A recently published meta-analysis
of G84E and prostate cancer risk in European Americans
(including 24 213 cases and 73 631 controls) reported a
pooled OR of 4.07 (95% CI 3.05–5.45) with an overall carrier
rate of 0.7% [12]. Akbari et al. [7] observed a signiﬁcant
diﬀerence in the frequency of G84E between prostate cancer
cases and controls in a large Canadian study; the prevalence
was < 1% in both groups (0.7 and 0.1%, respectively) in that
study.Work from the ICPCG identiﬁed a common haplotype
occurring in 95% of G84E carriers [5]. The frequency of
the haplotype is signiﬁcantly higher in Nordic countries,
suggesting a founder allele arising in this region of the world.
In a phylogenetic analysis of 40 haplotypes among 3239
Caucasian participants of the REDUCE trial, Chen et al. [11]
suggests that the G84E mutation is a relatively recent event,
occurring ∼ 220 years ago in Northern Europe. The variation
of the frequency of the G84E allele reported in North
American populations may therefore be inﬂuenced by
population substructure.
An Australian study of early-onset (<60 years at diagnosis)
prostate cancer cases unselected for family history (with a
carrier frequency of 1.4%) generated estimates of the
cumulative risk (to age 80 years) of prostate cancer associated
with the G84E mutation. Age-speciﬁc estimates of prostate
cancer penetrance varied from 4.6% by age 60 years to 45.7%
by age 80 years for a G84E carrier born in 1920; this
compared with a carrier born in 1950 where the cumulative
risk varied from 19.2% by age 60 years to 60.0% by age 80
years [13]. In our previous investigation of G84E in a prostate
biopsy series at the UM, the carrier rate was lower than
expected: just 4/948 men (0.42%). Despite the fact that 3/4
men were subsequently diagnosed with prostate cancer
(positive predictive value of 0.75%), we suggested there would
be limited utility in testing for G84E, because of its rarity in
the general population [14].
Studies have also examined the association between the G84E
mutation and the risk of breast and colon cancer, with some
inconsistency in their ﬁndings.While Akbari et al. [15]
observed no association between the variant and breast cancer
in a large case–control study, two other reports suggest a
three- to sixfold increase in the odds of breast cancer
associated with the mutation among women with familial
breast cancer (non-Ashkenazi BRCA1/2 negative) [8,16].
Laitinen et al. [8] reported no statistical diﬀerence in the
frequency of the mutation between colon cancer cases (1.6%)
and controls (0.9%).
In addition to G84E, additional rare HOXB13 mutations have
been detected by our group [2] and others [7]. Recently, a
novel rare mutation in HOXB13 (G135E) was reported to be
associated with prostate cancer among Chinese men [17]. In
that case series (n = 96), the entire coding region of the gene
was sequenced and a single patient was observed to have the
mutation. A subsequent case–control study of 671 cases and
1536 controls identiﬁed two additional carriers of G135E,
both cases. The variant, observed in the second of two highly
conserved myeloid ecotropic viral integration site (or
MEIS)-binding domains on exon 1 of the gene (G84E is
Table 2 Comparison of HoxB13 gene carriers with non-carriers according to selected prostate cancer characteristics.
Characteristic UM JHU All
GG, n (%) GA, n (%) P* GG, n (%) GA, n (%) P* GG, n (%) GA, n (%) P*
Total no. of patients** 1274 15 6941 111 8215 126
Age at diagnosis/surgery 0.43 0.0004 0.0003
≤60 years 721 (56.6) 10 (66.7) 4371 (63.0) 88 (79.3) 5092 (62.0) 98 (77.8)
>60 years 553 (43.4) 5 (33.3) 2569 (37.0) 23 (20.7) 3122 (38.0) 28 (22.2)
Family history 0.28 0.01 0.006
No 767 (60.2) 7 (46.7) 3948 (56.9) 49 (44.1) 4715 (57.4) 56 (44.4)
Yes 465 (36.5) 8 (53.3) 2447 (35.3) 50 (45.0) 2912 (35.4) 58 (46.0)
Unknown 42 (3.3) 0 (0.0) 546 (7.9) 12 (10.8) 588 (7.2) 12 (9.5)
Pathological Gleason score 0.56 0.95 0.95
<7 324 (25.4) 2 (13.3) 4008 (57.7) 65 (58.6) 4332 (52.7) 67 (53.2)
7 (3 + 4) 610 (47.9) 9 (60.0) 1767 (25.5) 29 (26.1) 2377 (28.9) 38 (30.2)
≥7 (4 + 3) 298 (23.4) 4 (26.7) 1137 (16.4) 17 (15.3) 1435 (17.5) 21 (16.7)
Unknown 42 (3.3) 0 (0.0) 29 (0.4) 0 (0.0) 71 (0.9) 0 (0.0)
Pathological T stage 1.0 0.51 0.52
≤T2/N0 1051 (82.5) 13 (86.7) 4870 (70.2) 80 (72.1) 5921 (72.1) 93 (73.8)
≥T3 or any T/N1 218 (17.1) 2 (13.3) 2040 (29.4) 29 (26.1) 2258 (27.5) 31 (24.6)
Unknown 5 (0.4) 0 (0.0) 31 (0.4) 2 (1.8) 36 (0.4) 2 (1.6)
*Chi-squared test or Fisher’s exact test for comparisons with small cells (excludes missing data). **Whites only.
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located in the ﬁrst), was predicted to have a deleterious eﬀect
on HOXB13 protein function using the POLYPHEN software
program [17].
HOXB genes are thought to regulate a number of processes
that inﬂuence cancer initiation and progression, and it appears
that there is some organ speciﬁcity in the function of diﬀerent
genes within this family in tumorigenesis [18].HOXB13 was
ﬁrst identiﬁed in 1996 [19], and is involved in early embryonic
development of the gland and prostate cell diﬀerentiation
[20].HOXB13 has been shown previously to regulate
transcriptional activity of the androgen receptor [21] critical
to prostate tumour growth. Furthermore, Norris et al. [22]
suggest a more complicated interaction between HOXB13 and
the androgen receptor, whereby HOXB13 can either act
directly on the androgen receptor to regulate the activity of
some genes or as a coregulator with the androgen receptor on
others.
There are limitations to the present investigation which need
to be considered when interpreting its ﬁndings. Despite the
fact that we were able to assemble a large case series for this
investigation, the low frequency of the mutation in the
population limited our ability to generate precise estimates of
the association between G84E and the characteristics under
investigation while also controlling for important covariates.
Nevertheless, our analysis stratifying associations of interest
by age at diagnosis (≤60 vs >60 years) suggests that a family
history of prostate cancer was more common among those
with the mutation, and more so among those diagnosed at an
earlier age. G84E carriers diagnosed at an earlier age were also
slightly more likely to have high grade disease (16.3%) than
non-carriers (14.0%), with the reverse relationship observed
among carriers diagnosed after age 60 years where they were
less likely to be diagnosed with high grade disease (17.9%)
than non-carriers (23.7%). These diﬀerences, however, were
not signiﬁcant.
In addition, despite the compatibility of our prevalence
estimates with previous reports, our ﬁndings may not be
generalizable to all men diagnosed with prostate cancer. The
fact that these men were appropriate candidates for surgery
would necessarily exclude men known to have advanced
disease at the time of diagnosis; however, the demographic
(age at diagnosis and race) and clinical (Gleason grade and
pathological tumour stage) characteristics of the cases
participating in the present investigation are similar to other
large cohorts of men with prostate cancer treated with radical
prostatectomy [23–25]. The relatively high proportion of the
patient population with a family history of prostate cancer
(∼36%) may reﬂect the referral patterns in the regions served
by the academic institutions as well as the educational level of
the patient population. Furthermore, it is likely that men with
a family history of disease are screened more frequently and
therefore may be more likely to be diagnosed with less
advanced stage disease. Our data indicate that ∼25% of
patients with a positive family history were diagnosed with
advanced (≥pT3a) stage disease as opposed to 28% of patients
without a family history (P = 0.001). Likewise, 15% of patients
with a positive family history were diagnosed with high
(≥ 4+3) grade disease as opposed to 19.5% of patients without
a family history (P < 0.001); therefore, the fact that this
mutation was associated with family history may potentially
have biased the ﬁndings related to stage toward the null and
may explain the absence of any association between G84E
with either grade or stage. Our analyses stratiﬁed on family
history, however, do not support this notion. The mutation
frequency among men with both high grade disease and a
positive family history was 1.3% compared with 1.4% among
men with high grade disease without a family history
(pχ2Breslow–Day = 0.19). Similar results were observed with respect
to tumour stage (data not shown).
In conclusion, the results of the present study conﬁrm the
presence of the G84E mutation in the HOXB13 gene in
prostate cancer and estimate its prevalence to be just under
2% of patients with prostate cancer.While no signiﬁcant
association was observed between G84E and tumour
pathological features, the increase in the frequency of this
mutation in patients with a positive family history and
earlier-onset disease reinforces the importance of uncommon,
but highly penetrant genes in the genetic epidemiology of
prostate cancer. Further investigation is clearly warranted to
reveal the underlying biological mechanism to explain this
relationship.
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